Collegium Pharmaceutical, Inc.
COLL
Positions held
Your positionsCOLL isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $719.80M | Enterprise value | $1.81B | Trailing P/E | 17.41 | Forward P/E | 3.33 |
| PEG | 0.64 | Price / book | 2.30 | Beta | 0.73 | Dividend yield | 0.00% |
| Revenue growth | 6.3% | Earnings growth | — | Gross margin | 89.4% | Operating margin | 5.7% |
| Profit margin | 5.9% | ROE | 17.6% | ROA | 5.8% | Debt / equity | 3.90 |
| Current ratio | 1.03 | Free cash flow | $324.04M | Analyst recommendation | strong_buy | Mean target | $49.00 |
| 52w high | $50.79 | 52w low | $21.43 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $200M | $194M | $205M | $209M | $188M | — |
| Op margin | 1.9% | 16.0% | 29.6% | 29.6% | 18.5% | — |
| Net income | -$15.1M | $14.5M | $17.0M | $31.5M | $12.0M | — |
| Gross margin | 55.2% | 60.6% | 62.5% | 61.7% | 57.7% | — |
| Gross profit | $110M | $117M | $128M | $129M | $108M | — |
| Operating income | $3.7M | $30.9M | $60.7M | $62.1M | $34.7M | — |
- Revenue +3% vs prior quarter ($200M vs $194M).
- Gross margin 55.2% (was 60.6% prior quarter).
- Operating margin compressed to 1.9%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $781M | $631M | $567M | $464M | — |
| Op margin | 22.9% | 26.4% | 29.5% | 7.2% | — |
| Net income | $62.9M | $69.2M | $48.2M | -$25.0M | — |
| Gross margin | 59.3% | 59.8% | 57.5% | 45.2% | — |
| Gross profit | $463M | $377M | $326M | $209M | — |
| Operating income | $178M | $167M | $167M | $33.3M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-07 · New Strong Sell Stocks for October 7th
2026-09-30 · 3 Healthcare Stocks That Concern Us
2026-09-28 · 3 Value Stocks That Fall Short
2026-09-23 · Collegium's Durable Cash Flow From Pain Portfolio Poised to Support Further Business Development, Oppenheimer Says
2026-09-23 · Oppenheimer Initiates Collegium Pharmaceutical at Outperform With $50 Price Target
2026-09-22 · 1 Oversold Stock Ready to Bounce Back and 2 We Find Risky
2026-09-21 · 1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
2026-09-09 · Leerink Partners Initiates Coverage on Collegium Pharmaceutical With Outperform Rating, $45 Price Target
2026-09-09 · Truist Cuts Price Target on Collegium Pharmaceutical to $49 From $58, Keeps Buy Rating
2026-09-08 · Collegium to Participate in Upcoming Investor Conferences
2026-08-15 · 5 Revealing Analyst Questions From Collegium Pharmaceutical’s Q2 Earnings Call
Price (daily)
Full chart · RSI · MACD · patterns